Nasus Pharma to Present Positive Clinical Results from Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting February 28, 2025 Click here Read More
Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis August 7, 2024 Click Here Read More
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine December 5, 2023 Click Here Read More
Nasus Pharma to Present Positive Clinical Results from Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting February 28, 2025
Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis August 7, 2024
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine December 5, 2023
Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice October 30, 2023
Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach July 28, 2022
Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague July 28, 2022
Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan® April 12, 2022
Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in June 23, 2021
